MEDICAINE INJECTION

Indications

• Used as a stabilizing agent in pharmaceuticals
• Used in food products as a preservative or acidity regulator

Dosage

Children: Refer to specific product information for dosing recommendations in children, as pediatric dosing guidelines will depend on the formulation and indication.

Adults: Refer to specific product information for detailed dosing recommendations, as the dosage of bitartrate can vary based on its use in different formulations.

Mechanism of action

Bitartrate acts primarily as a buffering agent, helping to maintain pH balance in formulations. It may enhance the solubility of specific active ingredients, thereby facilitating their absorption and efficacy. The precise mechanisms may vary depending on the specific bitartrate compound and its application.

Pharmacodynamics

The pharmacodynamics of bitartrate compounds are largely dependent on their specific use. Generally, bitartrate can influence the pharmacokinetics of co-administered drugs by altering their solubility and stability. This can lead to increased absorption and improved therapeutic outcomes. The effects on the central nervous system or other systems are not well characterized, as bitartrate is primarily used for its physicochemical properties rather than direct pharmacological effects.

Pharmacokinetics

The pharmacokinetics of bitartrate compounds largely depend on the specific formulation and the active ingredients involved. Generally, bitartrate salts are expected to dissociate in the gastrointestinal tract, contributing to the systemic availability of the active drug. The absorption, distribution, metabolism, and excretion profiles will vary based on the formulation and route of administration.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Bitartrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Bitartrate is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Anaphylaxis
• Cardiac arrest
• Severe asthma attacks
• Bradycardia
• Acute hypotension
• Local anesthetic adjunct to prolong action

Dosage

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Epinephrine acts on alpha-1 adrenergic receptors, leading to vasoconstriction and increased peripheral resistance, which raises blood pressure. It also stimulates beta-1 adrenergic receptors in the heart, increasing heart rate (positive chronotropic effect) and contractility (positive inotropic effect). Additionally, epinephrine activates beta-2 adrenergic receptors in the lungs, resulting in bronchodilation and improved airflow. These combined effects help to restore hemodynamic stability and improve respiratory function.

Pharmacodynamics

The pharmacodynamic effects of epinephrine include rapid onset of action, with significant cardiovascular and respiratory effects. It increases cardiac output and oxygen consumption, while also reducing pulmonary vascular resistance. The drug's effects can be observed within minutes and can last from several minutes to a few hours, depending on the route of administration. The use of epinephrine in life-threatening situations, such as anaphylactic shock, significantly improves survival rates.

Pharmacokinetics

Epinephrine is rapidly absorbed after subcutaneous or intramuscular injection, with peak plasma concentrations occurring within 20 minutes. It has a short half-life of approximately 2 to 3 minutes due to rapid metabolism by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) in the liver and other tissues. The drug is primarily excreted in urine as metabolites. The short duration of action necessitates repeated dosing or continuous infusion in critical care settings.

Contra-indications

• Hypersensitivity to epinephrine or any component of the formulation
• Cardiovascular diseases such as severe hypertension
• Hyperthyroidism
• Diabetes mellitus
• During general anesthesia with halogenated anesthetics

Adverse effects

• Increased heart rate (tachycardia)
• Hypertension
• Anxiety
• Tremors
• Nausea
• Vomiting
• Headache
• Palpitations
• Pulmonary edema
• Arrhythmias

Interactions

• Monoamine oxidase inhibitors (MAOIs) may potentiate the effects of epinephrine
• Beta-blockers may inhibit the effects of epinephrine
• Tricyclic antidepressants may increase cardiovascular effects
• Certain antihypertensives may have reduced efficacy

Precautions

• Use with caution in patients with cardiovascular disease
• Monitor blood pressure and heart rate closely during administration
• Consider potential interactions with other medications
• Use cautiously in patients with diabetes and hyperthyroidism

Pregnancy

Epinephrine should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Epinephrine is excreted in breast milk, caution is advised when administered to nursing mothers.

Storage

Store at room temperature, away from light. Do not freeze. Keep out of reach of children.

Formulations

• Inhalation solution
• Injection solution
• Auto-injector

Indications

• Local anesthesia for surgical procedures
• Topical anesthesia for minor skin procedures
• Management of pain in conditions such as postherpetic neuralgia
• As an antiarrhythmic agent for ventricular tachycardia
• Regional anesthesia in various surgical settings

Dosage

Children: Dosing in children is weight-based and should be determined according to guidelines

Adults: Dosage varies depending on the route of administration and specific procedure. For local anesthesia, a typical dose ranges from 5 mg to 300 mg depending on the area being anesthetized. For antiarrhythmic use, initial intravenous doses may be 1 to 1.5 mg/kg, with further doses based on clinical response. Always refer to specific clinical guidelines.

Mechanism of action

Lidocaine exerts its effects by binding to the intracellular portion of voltage-gated sodium channels, preventing sodium ions from entering the cell. This inhibition stabilizes the neuronal membrane and decreases the excitability and conduction of nerve impulses, leading to a reversible loss of sensation in the targeted area.

Pharmacodynamics

The onset of action of lidocaine is rapid, typically within minutes, and the duration of action can vary based on the formulation and route of administration. Its effects can be prolonged when used with vasoconstrictors, which reduce systemic absorption. Lidocaine also possesses antiarrhythmic properties and can be used to manage certain types of cardiac arrhythmias, specifically ventricular arrhythmias.

Pharmacokinetics

Lidocaine is well-absorbed following parenteral administration and has a bioavailability of approximately 100% when administered intravenously. It is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, producing both active and inactive metabolites. The elimination half-life varies, typically ranging from 1.5 to 2 hours in healthy individuals. About 90% of the drug is excreted in urine, mainly as metabolites.

Contra-indications

• Hypersensitivity to lidocaine or other amide local anesthetics
• Severe heart block
• Wolff-Parkinson-White syndrome
• Acute porphyria

Adverse effects

• CNS effects such as dizziness, drowsiness, and seizures
• Cardiovascular effects including hypotension and bradycardia
• Allergic reactions such as rash and anaphylaxis
• Local irritation, erythema, or edema at the injection site

Interactions

• Caution with other local anesthetics due to potential additive effects
• May enhance the effects of neuromuscular blockers
• Interactions with antiarrhythmic agents (e.g., phenytoin) may occur

Precautions

• Use with caution in patients with hepatic impairment
• Monitor for signs of toxicity, especially in high doses or rapid administration
• Consider underlying cardiovascular conditions before administration

Pregnancy

Lidocaine is classified as category B. It should be used during pregnancy only if clearly needed.

Breast-feeding

Lidocaine is excreted in breast milk in small amounts. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from light. Protect from freezing. Discard any unused solution after use.

Formulations

• Injectable solution
• Topical gel
• Transdermal patch
• Ointment

Indications

• Preservative in food and beverages
• Antioxidant in pharmaceutical formulations
• Reducing agent in biochemical applications

Dosage

Children: Refer to the specific product information or guidelines for dosing.

Adults: Refer to the specific product information or guidelines for dosing.

Mechanism of action

Pyrosulfite acts primarily as a reducing agent. It participates in oxidation-reduction reactions, donating electrons to other compounds. This ability allows it to stabilize and preserve other substances by preventing oxidative damage. It is involved in pathways such as thiosulfate oxidation II and the superpathway of sulfur oxidation.

Pharmacodynamics

The pharmacodynamics of pyrosulfite are largely related to its role as a reducing agent. It helps maintain the redox state of cells, which is crucial for various metabolic processes. By preventing oxidative stress, pyrosulfite can contribute to cellular stability and the maintenance of biochemical pathways that require a reduced environment.

Pharmacokinetics

The pharmacokinetics of pyrosulfite, including absorption, distribution, metabolism, and excretion, are not extensively documented in the literature. However, it is known that pyrosulfite can be absorbed through mucosal surfaces and may be metabolized in the liver. The compound is generally eliminated through renal pathways, and its metabolites may also be excreted in urine.